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Most published research on low-dose CT screening for lung cancer pertains to annual 
screening  (1). In this issue, Schreuder and colleagues explore the possibilities for extending 
the inter-screening interval on an individual basis (2) . Using data from the US National Lung 
Screening Trial (3), they build up a logistic regression model of risk of a lung cancer at the 
second annual screen or in the year following it, based on subject characteristics and 
radiological observations including nodule attributes at the first screen. The logistic model 
incorporates polynomial regression coefficients where appropriate. They compare their model 
with other possible prediction models for this specific endpoint and find it to be superior. 
The authors conclude that there is scope for extending the interval for some screenees. From 
their model, they project that for different risk thresholds, at the second screen, 2558 (10.4%), 
7544 (30.7%), 10,947 (44.6%), 16,710 (68.1%), and 20,023 (81.6%) of the 24,368 screens 
could have been omitted, at the cost of delayed diagnosis of 0 (0.0%), 8 (4.6%), 17 (9.8%), 
44 (25.3%), and 70 (40.2%) of the 174 lung cancers, respectively. 
These observations need to be validated prospectively and evaluated in terms of cost-
effectiveness, but they are certainly interesting and potentially very important. Another 
question which remains is, for the cancers whose diagnosis would be delayed as a result of 
postponing the second screen to two years after the first, what is lost in terms of stage of 
disease at diagnosis and the consequent effect on mortality?  
The authors report the (actual, observed) stage at diagnosis of the cancers which would be 
missed for the various thresholds. Apart from the lowest risk threshold, for which 10% of 
screens could be avoided with an estimated zero loss in terms of later diagnosis, for any given 
threshold, the majority of tumours which would have had their diagnosis delayed were 
diagnosed at stage I or II. Thus, the delay might well mean a substantial proportion having a 
good prognosis replaced by a poor one. This will be an important ingredient in a cost-
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effectiveness analysis. A future modelling exercise might target the issue of screening those 
whose tumours are most likely to benefit from early diagnosis, while not screening those 
destined either not to develop the disease or to be diagnosed at late stage despite our best 
efforts at early detection. 
We reiterate that the results here will need validation. However, they are important and will 
stimulate further work to improve the process of early detection of lung cancer for both 
provider and public. 
In the European position statement on lung cancer screening (EUPS)  (4), the management of 
prevalent lung nodules is discussed in detail and it was argued that nodule management will 
largely depend on size criteria, however, volumetry is now considered essential, but diameter 
cut-offs will also need to be provided for cases where segmentation is not possible. 
The Nelson trial group have analysed volume, volume doubling time, and volumetry-based 
diameter of 9681 non-calcified nodules detected by CT screening in 7155 participants and 
provided a very compelling argument to consider screening a sub-group of individuals on a 
biennial basis. 
They found that the Lung cancer probability was not significantly different between the 
participants who had nodules < 100 mm³ in volume and those participants who had no 
detected nodules (0·6% [95% CI 0·4–0·8] vs 0·4% [0·3–0·6]; p=0·17). The participants who 
had nodules between 100–300 mm³ had a significantly greater probability of developing lung 
cancer compared to participants with no screening-detected nodules (2·4% [95% CI 1·7–3·5]; 
p<0.0001 and were consider ‘indeterminate’ and requiring 3 or 12 months follow up CT scan, 
whist nodules of 300mm3 or greater had a significantly greater chance of developing lung 
cancer. 
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However, in about half of the NELSON participants, no pulmonary nodules were detected 
and their 2-year probability of developing a lung cancer was 0·4%.  Thus it may be argued 
that   they could have a screening interval of at least 2 years (5). 
 
There have been two major publications based on modelling screening intervals from the 
UKLS (6, 7) and the and the International Early Lung Cancer Action Program (7). Whilst 
Duffy et al estimated that two-yearly screening could potentially be more cost effective, 
Yankelevitz et al. argued that we should focus on how the interval between screens  affects 
the stage distribution prior to thinking about changing from annual screening intervals. 
Patz et al examined the NLST participants who had a negative prevalence screen and found 
that they had a substantially lower risk of developing lung cancer compared to individuals 
with a positive prevalence screen (8) thereby providing further support for the argument to 
consider biennial screening. 
 
The cost effectiveness of lung cancer screening has been analysed utilising microsimulation 
modelling by ten Haaf et al (9).Their results indicate that we have to seriously consider a 
range of screening scenarios, and especially the interactions between the smoking eligibility 
criteria as well as the screening interval, both of which  influence the cost-effectiveness of 
each scenario.  
 
The EUPS argued that future decisions on interval timing should be based on risk, 
psychosocial effects, cost-effectiveness, and the feasibility of implementation, all of which 
require further investigation. While we would argue that this remains the case, the results of 
Schreuder et al give valuable food for thought.  
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